Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Syndros save search
American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)
Published: 2022-03-04 (Crawled : 12:00) - biospace.com/
CRYO | $0.0001 0.0% 19K
|
Information
|
| O: 0.14%
H: 0.0%
C: -11.9%
america treatment trial cryo syndros
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
Published: 2022-03-03 (Crawled : 22:00) - biospace.com/
ANNX | $4.57 2.93% 2.84% 1.2M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: -6.21%
huntington treatment program disease preclinical bioscience syndros pre-clinical huntington’s disease
Tonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi Syndrome
Published: 2022-03-03 (Crawled : 20:00) - biospace.com/
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 46.52%
H: 28.57%
C: -9.18%
tnx-2900 treatment fda als drug drug designation syndros designation
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
Published: 2022-03-02 (Crawled : 14:00) - biospace.com/
AYTU | $2.84 1.79% 1.76% 6.9K
|
Health Technology
|
| O: -1.19%
H: 7.2%
C: 3.2%
ar101 treatment biopharma europe granted grant syndros designation
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
Published: 2022-02-08 (Crawled : 12:00) - globenewswire.com
BMRA | $0.7459 -1.86% -1.89% 35K
|
Health Technology
|
| O: -0.71%
H: 2.14%
C: 0.95%
infoods treatment trial food topline results positive topline syndros
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2022-02-04 (Crawled : 14:30) - biospace.com/
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
anavex treatment anavex®2-73 trial life science phase 3 syndros rett syndrome
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
Published: 2022-02-01 (Crawled : 13:00) - biospace.com/
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: -9.51%
anavex treatment trial phase 3 anavex®2-73 syndros rett syndrome
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
XERS | $1.73 -1.7% -1.73% 2M
|
Health Technology
|
| O: -4.35%
H: 9.6%
C: 6.57%
recorlev treatment biopharma syndros
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-01-31 (Crawled : 14:30) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 1.69%
H: 8.74%
C: 7.88%
covid-19 fast track designation treatment fda risk fast track respiratory covid grant syndros sabizabulin designation
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 1.39%
H: 6.65%
C: 6.09%
treatment fda drug orphan drug syndros designation
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome
Published: 2022-01-13 (Crawled : 14:30) - biospace.com/
XERS | $1.73 -1.7% -1.73% 2M
|
Health Technology
|
| O: -0.44%
H: 2.63%
C: -0.88%
rare treatment als syndros
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Published: 2022-01-12 (Crawled : 13:30) - biospace.com/
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: 1.71%
H: 1.17%
C: -3.83%
phase 3 syndros treatment
Global Hepatorenal Syndrome Treatment Market Research Report (2021 to 2026) - by Type, Treatment, End-user and Region
Published: 2022-01-04 (Crawled : 21:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.57%
H: 1.57%
C: 0.28%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.68%
H: 0.0%
C: 0.0%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: 0.0%
EW | $85.94 -0.59% 0.0% 3.9M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: 0.0%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: 0.0%
LJPC | $6.22 0.0%
|
Health Technology
|
| O: 0.21%
H: 4.19%
C: -6.06%
CPIX | $1.65 6.02% 790
|
Health Technology
|
| O: -13.36%
H: 0.0%
C: 0.0%
BIVI | $0.4874 -0.21% -0.21% 490K
|
Health Technology
|
| O: 2.86%
H: 12.1%
C: 12.1%
treatment renal research syndros
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
Published: 2021-12-08 (Crawled : 14:00) - biospace.com/
AYTU | $2.84 1.79% 1.76% 6.9K
|
Health Technology
|
| O: 1.52%
H: 0.5%
C: -7.0%
treatment fda biopharma drug orphan drug syndros designation
Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
Published: 2021-12-08 (Crawled : 13:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
treatment fda disease oda kidney syndros
Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment
Published: 2021-11-04 (Crawled : 11:00) - globenewswire.com
BMRA | $0.7459 -1.86% -1.89% 35K
|
Health Technology
|
| O: -1.34%
H: 1.22%
C: -0.23%
food treatment test patent syndros
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
MIRM | News | $23.83 1.1% 1.09% 340K
|
Health Technology
|
| O: -0.19%
H: 4.45%
C: 2.4%
treatment syndros lancet
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
Published: 2021-09-29 (Crawled : 18:00) - biospace.com/
MIRM | News | $23.83 1.1% 1.09% 340K
|
Health Technology
|
| O: 1.92%
H: 12.51%
C: -2.3%
treatment fda fda approval syndros order
GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.07%
H: 0.34%
C: -6.71%
treatment fda phase 1 clinical hold syndros
Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: 1.19%
H: 3.1%
C: 1.33%
treatment orphan drug europe drug syndros designation rett syndrome tsha-102
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.